BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rybicka M, Bielawski KP. Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection. Microorganisms. 2020;8. [PMID: 32942584 DOI: 10.3390/microorganisms8091416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
2 Ding R, Long J, Yuan M, Zheng X, Shen Y, Jin Y, Yang H, Li H, Chen S, Duan G. CRISPR/Cas12-Based Ultra-Sensitive and Specific Point-of-Care Detection of HBV. Int J Mol Sci 2021;22:4842. [PMID: 34063629 DOI: 10.3390/ijms22094842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ndeboko B, Omouessi ST, Ongali B, Mouinga-Ondémé A. Cell Penetrating Peptides Used in Delivery of Therapeutic Oligonucleotides Targeting Hepatitis B Virus. Pharmaceuticals (Basel) 2020;13:483. [PMID: 33371278 DOI: 10.3390/ph13120483] [Reference Citation Analysis]
4 Gao L, Yang J, Feng J, Liu Z, Dong Y, Luo J, Yu L, Wang J, Fan H, Ma W, Liu T. PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication. Front Immunol 2022;13:856463. [DOI: 10.3389/fimmu.2022.856463] [Reference Citation Analysis]
5 Ouchida T, Takamatsu S, Maeda M, Asuka T, Morita C, Kondo J, Ueda K, Miyoshi E. Challenges in the Application of Glyco-Technology to Hepatitis B Virus Therapy and Diagnosis. Viruses 2021;13:1860. [PMID: 34578441 DOI: 10.3390/v13091860] [Reference Citation Analysis]
6 Li Y, Zhou J, Li T. Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment. Front Mol Biosci 2022;9:879817. [DOI: 10.3389/fmolb.2022.879817] [Reference Citation Analysis]
7 Yang C, Chen H, Zhou B, Yin J, Cao G, Hou J, Jiang D. The effects of the interactions of STAT4 rs7574865 with HBV mutations on the risk of hepatocellular carcinoma. Mol Carcinog 2022. [PMID: 35880842 DOI: 10.1002/mc.23449] [Reference Citation Analysis]
8 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
9 Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes. J Clin Med 2021;10:2926. [PMID: 34210105 DOI: 10.3390/jcm10132926] [Reference Citation Analysis]
10 Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Reference Citation Analysis]
11 Chemin I, Pujol FH. Special Issue: “Updates on HBV Infection”. Microorganisms 2022;10:580. [DOI: 10.3390/microorganisms10030580] [Reference Citation Analysis]
12 Hamdi M, Elmowafy E, Abdel-Bar HM, ElKashlan AM, Al-Jamal KT, Awad GAS. Hyaluronic acid-entecavir conjugates-core/lipid-shell nanohybrids for efficient macrophage uptake and hepatotropic prospects. Int J Biol Macromol 2022;217:731-47. [PMID: 35841964 DOI: 10.1016/j.ijbiomac.2022.07.067] [Reference Citation Analysis]
13 Meneghello BHDS, Soares MMCN, Silva VCM, Lemos MF, Cervato MC, Caetano Filho J, Sitnik R, Estécio TCH, Compri AP, Pinho JRR, Moreira RC. Hepatitis B in the Northwestern region of Sao Paulo State: genotypes and resistance mutations. Rev Inst Med Trop Sao Paulo 2021;63:e78. [PMID: 34755817 DOI: 10.1590/S1678-9946202163078] [Reference Citation Analysis]